Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332019 | Prostate | Tumor | regulation of protein modification by small protein conjugation or removal | 92/3246 | 242/18723 | 1.20e-14 | 1.73e-12 | 92 |
GO:003139619 | Prostate | Tumor | regulation of protein ubiquitination | 76/3246 | 210/18723 | 3.96e-11 | 2.68e-09 | 76 |
GO:007233119 | Prostate | Tumor | signal transduction by p53 class mediator | 63/3246 | 163/18723 | 7.82e-11 | 4.96e-09 | 63 |
GO:004225419 | Prostate | Tumor | ribosome biogenesis | 96/3246 | 299/18723 | 2.76e-10 | 1.51e-08 | 96 |
GO:004227319 | Prostate | Tumor | ribosomal large subunit biogenesis | 34/3246 | 72/18723 | 4.52e-09 | 1.82e-07 | 34 |
GO:004225519 | Prostate | Tumor | ribosome assembly | 29/3246 | 61/18723 | 5.06e-08 | 1.54e-06 | 29 |
GO:190179619 | Prostate | Tumor | regulation of signal transduction by p53 class mediator | 38/3246 | 93/18723 | 7.68e-08 | 2.14e-06 | 38 |
GO:005134819 | Prostate | Tumor | negative regulation of transferase activity | 81/3246 | 268/18723 | 1.30e-07 | 3.35e-06 | 81 |
GO:190332119 | Prostate | Tumor | negative regulation of protein modification by small protein conjugation or removal | 38/3246 | 95/18723 | 1.49e-07 | 3.76e-06 | 38 |
GO:190179819 | Prostate | Tumor | positive regulation of signal transduction by p53 class mediator | 16/3246 | 25/18723 | 2.69e-07 | 6.21e-06 | 16 |
GO:003139719 | Prostate | Tumor | negative regulation of protein ubiquitination | 34/3246 | 83/18723 | 3.41e-07 | 7.67e-06 | 34 |
GO:000636417 | Prostate | Tumor | rRNA processing | 69/3246 | 225/18723 | 5.98e-07 | 1.26e-05 | 69 |
GO:001607217 | Prostate | Tumor | rRNA metabolic process | 71/3246 | 236/18723 | 9.17e-07 | 1.79e-05 | 71 |
GO:000150314 | Prostate | Tumor | ossification | 109/3246 | 408/18723 | 1.13e-06 | 2.14e-05 | 109 |
GO:000002819 | Prostate | Tumor | ribosomal small subunit assembly | 12/3246 | 19/18723 | 1.09e-05 | 1.56e-04 | 12 |
GO:005143817 | Prostate | Tumor | regulation of ubiquitin-protein transferase activity | 22/3246 | 53/18723 | 3.06e-05 | 3.66e-04 | 22 |
GO:000047014 | Prostate | Tumor | maturation of LSU-rRNA | 14/3246 | 28/18723 | 7.53e-05 | 7.86e-04 | 14 |
GO:004227419 | Prostate | Tumor | ribosomal small subunit biogenesis | 26/3246 | 73/18723 | 1.36e-04 | 1.26e-03 | 26 |
GO:003447013 | Prostate | Tumor | ncRNA processing | 94/3246 | 395/18723 | 6.02e-04 | 4.31e-03 | 94 |
GO:000002719 | Prostate | Tumor | ribosomal large subunit assembly | 12/3246 | 27/18723 | 9.52e-04 | 6.20e-03 | 12 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL3 | insertion | Nonsense_Mutation | novel | c.451_452insAATGCCTGCCTGAAAGTCGGTTGTGAG | p.Ser151delinsLysCysLeuProGluSerArgLeuTerGly | p.S151delinsKCLPESRL*G | P39023 | protein_coding | | | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL3 | insertion | Nonsense_Mutation | novel | c.481_482insACCAGTAACACTGAAATGCCTGCCTGAAAGTCGGTTGTGAG | p.Arg161HisfsTer3 | p.R161Hfs*3 | P39023 | protein_coding | | | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
RPL3 | insertion | Frame_Shift_Ins | novel | c.114_115insT | p.Lys39Ter | p.K39* | P39023 | protein_coding | | | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL3 | insertion | Frame_Shift_Ins | novel | c.415_416insCTTCTCCCTT | p.Asp139AlafsTer5 | p.D139Afs*5 | P39023 | protein_coding | | | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RPL3 | insertion | Nonsense_Mutation | novel | c.446_447insATTCAACTGGTGACTCACCAGTAACACTGAAATGCCTGC | p.Asp149delinsGluPheAsnTrpTerLeuThrSerAsnThrGluMetProAla | p.D149delinsEFNW*LTSNTEMPA | P39023 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL3 | deletion | Frame_Shift_Del | novel | c.481delC | p.Arg161ValfsTer20 | p.R161Vfs*20 | P39023 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
RPL3 | SNV | Missense_Mutation | | c.1183N>A | p.Asp395Asn | p.D395N | P39023 | protein_coding | deleterious(0.03) | benign(0.041) | TCGA-FU-A3EO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RPL3 | SNV | Missense_Mutation | | c.1086N>C | p.Lys362Asn | p.K362N | P39023 | protein_coding | tolerated(0.2) | benign(0.001) | TCGA-FU-A3YQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RPL3 | SNV | Missense_Mutation | novel | c.90G>T | p.Lys30Asn | p.K30N | P39023 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
RPL3 | SNV | Missense_Mutation | novel | c.1036A>G | p.Thr346Ala | p.T346A | P39023 | protein_coding | deleterious(0.05) | possibly_damaging(0.803) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |